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1. Introduction 
Adult stem cells are a population of immature cells that have the capability of self renewal 
to provide the human body with a constant source of cells for maintaining healthy tissues or 
replacing those that are damaged.  Our present day scientific developments alongside 
clinical experiences have collectively consolidated our understanding of the signals that 
mediate stem cell lineage commitment and differentiation. From this, the concept of using 
adult stem cells to repopulate chronically diseased organs is now a feasible option for 
regenerative medicine.  
Whilst the use of human embryonic stem cells in the clinical setting has been 
overwhelmingly marred by its oncogenic potential as well as ethical concerns, the rate of 
progress in understanding the complex developmental plasticity of adult stem cells, in 
particular those derived from the bone marrow, has successfully allowed their use for 
translational research with unattached ethical issues. The pioneering use of bone marrow 
stem cells in the 1960s as a viable treatment option for leukaemia, myeloma and lymphoma 
has come a long way since then. Today we are able to use these stem cells to give rise to 
bone and cartilage (1) and to repair both cardiac and liver function (2, 3). Since a detailed 
review for each of these exciting developments is too broad for this chapter, we will mainly 
focus on the use of bone marrow derived stem cell for the treatment of chronic liver disease. 
2. Chronic liver disease 
Liver cirrhosis is the end stage of chronic liver disease and is associated with many serious 
systemic complications resulting from both liver failure and portal hypertension. This 
condition has a poor prognosis and is difficult to treat. In the UK alone as many as one in 
ten people have some form of liver disease where many die prematurely as a result (4). 
Liver disease is currently the fifth most common cause of mortality in the UK for both men 
and women and whilst the mortality rates for coronary heart disease, cancer, respiratory 
and cerebro-vascular diseases are falling, the death rates from all types of liver disease in 
England and Wales over the last 25 years showed over 150% increase in men and 100% in 
women (5). This significant upward trend clearly indicates a need to plan ahead for the 
health service. Worldwide, the common causes of liver fibrosis and cirrhosis include 
hepatitis B, hepatitis C and alcohol consumption. Other causes include immune mediated 
damage, genetic abnormalities, and non-alcoholic steatohepatitis which are mostly 
associated with diabetes and metabolic syndrome (6-8). 
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3. Cirrhosis 
Liver cirrhosis or fibrosis is a common progressive pathological lesion of chronic liver 
disease that occurs in response to various liver-damaging factors. Cirrhosis is defined as the 
histological development of regenerative nodules surrounded by fibrous bands which leads 
to portal hypertension; the development of hepatocellular carcinoma and end-stage liver 
disease. Over the past two decades the main cellular and molecular mechanisms of cirrhotic 
initiation and progression have been clearly defined. Various causative factors including 
hepatitis virus infection; ischemia; parasite infection; abnormal copper or iron load, all result 
in chronic inflammation which initially leads towards an excessive synthesis of the 
extracellular matrix (ECM). Activated hepatic stellate cells; injured or regenerated 
hepatocytes; Kupffer cells; sinusoidal cells and natural killer (NK) cells all produce 
cytokines and immunoreactive factors which exert various biological effects in an autocrine 
and paracrine manner to initiate fibrotic growth (9-12). 
The detailed understanding of the natural history and pathophysiology of cirrhosis has 
resulted in better management of its complications to improve the quality of life of patients. 
Whilst pharmacological treatments can halt progression to decompensated cirrhosis, 
orthotopic liver transplantation (OLT) still remains the only highly successful and curative 
option for end stage cirrhosis. Survival data from the United Network of Organ Sharing 
(UNOS) study in 2004 indicated a survival rate of only 61% at 8 year post transplantation  
(13). OLT cannot be sustained as the only option for advanced liver failure. The limited 
availability of organs for a constantly growing list of patients requiring transplant in 
addition to issues of compatibility and comorbid factors means that not everyone is eligible 
for transplantation. There is therefore is an unmet need to find a suitable alternative.  
4. Hepatocyte transplantation 
Hepatocyte transplantation has been identified as a promising alternative to OLT for certain 
liver-based metabolic disorders and acute liver failure. With the advantage of preserving the 
native liver, hepatocyte transplantation is less invasive and can be performed repeatedly to 
allow a higher chance for improved recovery in patients with acute liver failure (14-16). The 
mechanisms by which intraportally injected donor hepatocytes engraft into the host liver 
parenchyma involves cell migration within the liver sinusoids (17). These cells become 
trapped causing portal hypertension and ischemic–reperfusion (18, 19). This consequently 
initiates clearance by the innate immune system where the associated release of cytokines 
induces vascular permeability thus allowing surviving hepatocytes to translocate through 
the sinusoidal fenestrations and integrate into the liver parenchyma (20). Although the 
initial engraftment success of hepatocytes after transplantation is low, repeated hepatocyte 
transplantation in animal models have shown a sufficient increase in the number of 
engrafted cells to allow recovery from some metabolic defects (21). Isolation of hepatocytes 
is carried out from donor liver that are unused or not suitable for whole organ 
transplantation. Cells harvested from a single donor have the advantage of being used for 
multiple recipients in addition to being cryopreserved for use in emergency treatment of 
acute liver failure or  for repeat treatment of liver-based metabolic disorders (22-24).  To date 
hepatocyte transplantation has only been used to address single gene defects and some 
metabolic disorders where the risks associated with OLT are not justified or are aimed at 
avoiding or postponing liver transplantation. The most successful clinical outcomes of OLT 
have been in patients with metabolic disorders including those with urea cycle defects (23, 
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24); Crigler-Najjar syndrome type 1 (CN1) (25, 26); glycogen storage disease type 1 (27) and 
Factor VII deficiency (28). Although it was initially thought that transplantation of 
hepatocytes would be less immunogenic than whole organ transplantation, data from 
animal models demonstrated that the innate immune system clears a significant amount of 
hepatocyte irrespective of whether syngeneic or allogeneic cells are used (18).  As a result 
most transplant facilities use the same immunosupressive treatment as for liver 
transplantation (29). Since the clinical outcome following hepatocyte transplantation is still 
highly variable due to a multitude of factors including fibrotic damage to the liver which 
limits the proper engraftment of cells; the availability of the cells required to provided 
sufficient liver function over repeated infusion per patient, and often the very marginal 
quality of the cells isolated from donor liver, a new and readily available cell source must be 
identified. This strong demand has fuelled the interest in haematopoietic stem cells for 
treating acute liver failure. 
5. The developmental plasticity of adult stem cells 
It had previously been assumed that adult stem cells were lineage restricted, however the 
culmination of research over the past decade has now fully confirmed the remarkable 
developmental plasticity of human adult stem cells. The ability of adult bone marrow 
derived myogenic progenitors to participate in the regeneration of damaged skeletal muscle 
(30); ischemic myocardium (31-33); neurogenesis (34, 35) and  the conversion of adult neural 
stem cells back into hematopoietic cells (36), redefined the biology of development. It was 
now accepted that the original three germs layers were not necessarily vital for 
transdifferentiation to occur (37). This implied that adult stem cells could exhibit similar 
pluripotency as embryonic stem cells. 
6. Generation of hepatocytes by haematopoietic stem cells 
The demonstration that adult bone marrow stem cells could differentiate towards a hepatic 
lineage was made almost a decade ago. Two independent research groups showed that the 
adult rat bone marrow contains a subpopulation of cells (about 3%) co-expressing the 
haematopoietic stem cell markers (CD34+, c-Kit, Thy-1); α-fetoprotein (AFP) and c-met. When 
they cultured this crude extract of bone marrow with hepatocyte growth factor (HGF) and 
epidermal growth factor (EGF), they were able to detect the expression of albumin, a marker of 
fully differentiated hepatocyte (38, 39). Over the years further refinement of the in vitro culture 
conditions led to the differentiation of haematopoietic cells that expressed more mature liver 
specific transcription factors including human Hepatocyte nuclear factor-1α (HNF-1α); 
cytokeratin (CK8); CK19 and AFP (40, 41). Studies on human adult bone marrow similarly 
confirmed their capability of differentiating into liver like cells (42, 43) where numerous 
cytokines and growth factors were shown to be important for driving this differentiation 
under in vitro conditions (44-46). More interestingly was the discovery that exposing rat 
haematopoietic stem cells to injured liver tissues induced the expression of functional 
hepatocyte factors (CK18, albumin and transferrin) (47). This suggested that the liver micro-
environment alone was sufficient in providing the appropriate cues for inducing stem cell 
conversion towards the hepatic lineage.  Several human post-mortem studies confirmed this 
observation where the presence of bone marrow derived cells were found in the liver.  Theise 
et al., (2000) investigated archival autopsy and biopsy liver specimens from recipients of sex-
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mismatched therapeutic bone marrow transplantation and OLT (48). By immunohistochemical 
staining for CK8, CK18 and CK19, they identified hepatocytes and cholangiocytes of bone 
marrow origin as well as the detection of the Y-chromosome by fluorescent in situ 
hybridization (FISH). Using double staining analysis, they found a large number of engrafted 
hepatocytes (4%-43%) and cholangiocytes (4%-38%) - that were bone-marrow derived- 
replenishing the hepatic parenchyma. Despite a general variability of this observation amongst 
parallel studies (49, 50), the ultimate conclusion was that bone marrow derived 
haematopoietic stem cells were able to successfully engraft into the liver and gradually adopt 
a phenotype very similar to the hepatic lineage. 
7. Human studies 
Today, the most widely studied adult stem cells are derived from the hematopoietic lineage. 
Hematopoietic stem cells (HSCs) form part of the bone marrow compartment which 
constitutes a heterogenous population of mesenchymal stem cells; committed progenitor 
cells and non-circulating stromal cells. The identification of HSCs from the bone marrow 
compartment is largely based on the expression of cell surface markers. Detecting the cluster 
of differentiation, CD34 is generally used in human studies as a surrogate marker for  
progenitor stem cells although there also exists a subpopulation of more primitive HSCs 
which do not express CD34 (51, 52). Despite the numerous studies that have shown bone 
marrow stem cells can give rise to hepatocytes, their use as a therapeutic agent is still in its 
infancy. Many studies are still at a pilot stage requiring randomisation and controls, 
however those reported show interesting results that require conformation. The first clinical 
study was performed by a German group, am Esch et al., (2005), where three patients were 
infused with autologous CD133+ cells subsequent to portal vein embolisation of right liver 
segments (3). A computerised tomography (CT) scan for volume analysis of the left lateral 
segments showed a 2.5 fold increase in growth rate of the three patients when compared to 
the control group without bone marrow stem cell administration. Despite the small number 
of patients and the lack of adequately sized randomised control group, this data showcased 
the promising potential of bone marrow derived stem cells in enhancing liver regeneration. 
A year later, a parallel study was reported by Gordon et al., (2006) which included a phase I 
clinical trial on five patients with liver insufficiency (53). These patients were given 
granulocyte colony-stimulating factor (G-CSF) to mobilise their stem cells for collection by 
leukapheresis followed by purification of CD34+ expressing cells which were then injected 
into either the portal vein or hepatic artery. Three of the five patients showed improvement 
in serum bilirubin whereas four out of the five patients displayed significant increase in 
serum albumin.  Clinically, the procedure was well tolerated with no observed procedure-
related complications and the data concluded that there was a marked contribution of the 
stem cells towards regeneration of the damaged liver (53). In another independent study, 
Terai et al., (2006) enrolled nine patients with liver cirrhosis where they were injected with 
autologously derived bone marrow stem cells enriched for the expression of CD34+, CD45+ 
and c-kit+. These patients were followed for 24 weeks where they showed a significant 
improvement in serum albumin levels in addition to significantly improved Child-Pugh 
scores (54). A year later, Rajkumar et al., (2007) reported another small scale trial where 22 
patients with chronic liver disease (Child-Pugh scores B-C) were enrolled (55). 200ml to 
300ml of bone marrow aspirate were subjected to density gradient fractionation for isolation 
of CD34+ cells. These were then administered intravenously through the median cubital 
www.intechopen.com
 
Stem Cell Therapy for Patients  with Chronic Liver Disease 
 
505 
vein. Liver function tests; ultrasound and CT scans were performed before, 4 weeks and 8 
weeks following cell infusion. 32% of the patients showed a drop in bilirubin levels; 67% of 
the patients showed an increase in serum albumin levels and 73% showed reduction in 
ascites. No patients from this study showed severe adverse effects following transfusion and 
the overall quality of life index was significantly improved in the majority (82%) (55). In 
2007, Mohamadnejad et al., (56, 57) performed two clinical studies in patients with 
decompensated liver cirrhosis. In the first study they treated four patients each with 31.73 x 
106 of  cultured autologous mesenchymal stem cells, infused through a peripheral vein. The 
Phase I study demonstrated no side effects and the quality of life of all four patients 
improved by the end of follow-up. Furthermore, the model for end-stage liver disease scores 
of two patients (patient 1 & patient 4) showed marked amelioration in their Child Pugh 
scores by the end of follow-up. In the second study, they treated four patients with 
autologous CD34+ cells isolated from the bone marrow, which was slowly infused through 
the hepatic artery of the patients. In two patients they observed mild albumin improvement, 
however, the health of two patients further deteriorated where one died of liver failure a 
few days after the transplantation. This trial was prematurely stopped due to the severity of 
the side effects where it was concluded that infusion of CD34+ stem cells through the hepatic 
artery was not safe in decompensated cirrhosis, but suggested that it may be beneficial to 
use alternative routes to transplant CD34+ cells. Having corroborated the use of bone 
marrow stem cells as a regenerative therapy and demonstrated their safety in patients with 
liver insufficiency, Pai et al.,(2008) conducted a prospective clinical efficacy study of 
expanded adult CD34+ stem cells infused into the hepatic artery in nine patients with 
alcoholic liver cirrhosis (ALC) to determine whether clinical benefit was conferred (58). The 
primary end point was to assess the safety of infusing autologous stem cells into the hepatic 
artery of these patients; the secondary end point was to assess the improvement in liver 
function through serological and biochemical analysis; and to determine whether there were 
any symptomatic improvements.  Following CD34+ stem cell infusion, CT scans showed 
normal enhancement in the liver parenchyma, with no evidence of focal liver lesions; 
additionally, duplex Doppler ultrasound scans showed normal flow in the portal veins and 
hepatic artery. To corroborate the safety and efficacy of improving liver function in patients 
with liver cirrhosis, Levicar et al., (2008) then reported the results from a long-term follow-
up (12-18 months) of patients with chronic liver disease injected with CD34+ enriched stem 
cells (59). During this time the patients were monitored for side effects, toxicity and changes 
in clinical, haematological and biochemical parameters. All the patients tolerated the 
treatment protocol without any complications or side effects related to the procedure. Four 
patients showed an initial improvement in serum bilirubin level, which was maintained for 
up to 6 months; whilst only a marginal increase in serum bilirubin was observed in three of 
the patients at 12 months. Only one patient showed an increase in serum bilirubin over 
slightly longer period of 18 months post-infusion. CT scans and serum AFP monitoring did 
not show any lesions or tumor formation in the patients. This successful study provided the 
basis for subsequent trials where more recently Li Nan et al., (2010) reported the clinical 
outcome of autologous CD34+ infusion in patients with hepatitis induced liver failure (60). 
Twenty seven patients with Child- Pugh C cirrhosis were enrolled of which 22 were positive 
for Hepatitis B and 5 were positive for Hepatitis C. 50ml to 120ml of bone marrow aspirate 
were subjected to a Percoll gradient for the isolation of myeloid stem cells. 20 of the patients 
received cell infusion via the hepatic portal vein whilst 7 patients were infused via the 
hepatic artery using the Seldinger percutaneous technique. The patients were closely 
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monitored for 3 months following transplantation where it was initially noticed that liver 
function tests decreased for 3 days. The authors attributed this with the contrast media used 
to perform arteriography. Since all the patients had Child- Pugh C cirrhosis, the contrast 
media may have aggravated liver injury. Despite this, the patients did subsequently show 
an improvement in liver function by 1 week of transplantation. The most significant 
recovery was seen at 3 months post procedure where total bilirubin and albumin levels were 
highest. Overall, an improved clinical outcome was observed in the majority of the patients 
where jaundice was resolved and ascites improved 3 months after therapy. From this cohort 
of patients, two died, one due to peritoneal cavity infection and liver failure, and the second 
from a massive hemorrhage of the upper alimentary tract. The latest clinical study on patients 
with end stage liver disease has been reported by Nikeghbalian et al., (2011) (61). Six patients 
were intraportally injected with autologous bone marrow-derived CD133+ cells. This arm of 
patients were compared with patients subjected short term infusion (6months) and long term 
infusion (12 months) of mononuclear cells. Liver function test was positive at 24 months of 
follow up in all the patients enrolled in this trial. Since there were no differences between the  
groups receiving MNC or CD133+ cell, this recent study has highlighted the versatility of   
bone marrow-derived progenitor mononuclear stem cells irrespective of the subpopulation of 
their cluster of differentiation markers. Furthermore this study also confirms their safe use to 
circumvent the need for liver transplantation in end stage liver disease. 
The culmination of clinical trials thus far mentioned have shown a trend towards decreased 
serum fibrosis markers and improvements in bilirubin, albumin and Child-Pugh scores 
following stem cell infusion. The past decade has marked an important progress for 
regenerative liver therapy; however the accumulated data is still in its infancy.  It is still not 
clear whether the route of infusion is important or whether mobilization of myeloid 
progenitor stem cells with G-CSF without leukapheresis is sufficient.  Until more is learnt 
about the mechanisms by which HSCs contribute to hepatocyte regeneration, and the 
mechanism of clinical benefit in the recipient patients; controversy will inevitably shadow 
this form of treatment. Some authors have proposed that the observed conversion of infused 
stem cell to hepatocytes is simply a byproduct of cell fusion with no true induction of 
transdifferentiation (59, 60). Others have suggested that instead of adopting a new lineage, 
the stem cells indirectly serve a regenerative capability by stimulating activation of tissue 
specific stem cells and by inducing the release of vascular endothelial growth factor (VEGF) 
thereby increasing the blood supply to the cells and aiding in repair of the damaged tissue 
(61, 62). There are reports that also suggest HSCs may act in a regenerative capacity simply 
by inducing the expression of the B-Cell leukemia/lymphoma-2 gene (Bcl-2) and 
interleuking-6 (IL-6) in a paracrine manner thus suppressing apoptosis and inflammation of 
the surrounding tissue (62-64). In addition to these uncertainties, the homing mechanism of 
infused adult stem cells to the liver also remains unclear. There are suggestions that 
chemokines similar to stroma derived factor 1 may be involved, however, this remains to be 
validated (65). Although the application of stem cell therapy will not be prevented despite 
an incomplete understanding of the mechanisms involved, a clearer picture will ultimately 
enable better tailoring of stem cell therapy to the disease in question.  
8. Current limitations  
For cell replacement therapy is still too early to demonstrate its long-term effectiveness or its 
improvement in survival rate and in the quality of life. This will undoubtedly have to be 
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evaluated by more randomised control studies in the future. A standardised protocol will 
need to be established for the most efficient route of delivering infused HSCs; for the 
efficient long term culture of HSCs; for the optimal cell density and repeated transplantation 
required to re-establish liver function. 
9. Future prospects  
Autologous bone marrow infusion for patients with chronic liver disease has been shown to 
improve liver function parameters in contrast to observations accompanied by abstinence 
from alcohol. The degree of effectiveness of this therapy will likely to vary among different 
patients. Although the mechanisms underlining adult stem cell plasticity is still far from 
being fully characterised, the general enthusiasm regarding its potential clinical implication 
is heightened by the numerous clinical trials currently underway. In hepatology, the data 
presented here provides hope that human adult stem cells could eventually be used in tissue 
replacement protocols for the treatment of inherited and acquired end-stage liver diseases. 
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